Cemiplimab clinical trials
Also written Libtayo and REGN2810.
How each study uses cemiplimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cemiplimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Sept 2018 · LIBTAYO · BLA 761097 (FDA, Drugs@FDA)
- European Union
- 28 Jun 2019 · Libtayo · EMEA/H/C/004844 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Libtayo
- 71
Studies by the year they started
129 studies that test it; most in 2026 (27); 6 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 9 |
| 2019 | 6 |
| 2020 | 12 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 15 |
| 2025 | 23 |
| 2026 | 27 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 42 · Other 93
Regeneron Pharmaceuticals (35) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · National Cancer Institute (NCI) (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Columbia University (3) · Mayo Clinic (3)
Often tested with
Tested in the same studies.
Fianlimab (16) · Cetuximab (5) · Paclitaxel (4) · Gemcitabine (3) · Carboplatin (3) · Dupilumab (3) · Pembrolizumab (3) · Sarilumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 20, 2 in phase 3
Studies that test cemiplimab, phase 3 first.
- Mar 2027A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3 · Regeneron Pharmaceuticals
- Jul 2027A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCPhase 3 · Maia Biotechnology
- Nov 2026REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerPhase 2 · Mark Stein
- Nov 2026A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaPhase 2 · Regeneron Pharmaceuticals
- Nov 2026A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersPhase 1/2 · Regeneron Pharmaceuticals
- Dec 2026Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCPhase 1/2 · Icahn School of Medicine at Mount Sinai
- Dec 2026A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin CancerPhase 2 · University of Southern California
- Jan 2027Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast CancerPhase 2 · City of Hope Medical Center
- Feb 2027Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaPhase 1 · National Cancer Institute (NCI)
- Apr 2027A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabPhase 1 · Regeneron Pharmaceuticals
Studies
Open first, then newest update. How each study uses cemiplimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 135
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896Written as Cemiplimab
- Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingPhase 2Medical University of South CarolinaNCT07720167Written as Cemiplimab
- Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07387198Written as Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingPhase 3Regeneron PharmaceuticalsNCT06246916Written as cemiplimab
- Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon CancerNot yet recruitingPhase 2John Strickler, M.D.NCT07224022Written as Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06981325Written as Cemiplimab
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)RecruitingPhase 2Columbia UniversityNCT07433673Written as Cemiplimab
- Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialRecruitingPhase 2University of Maryland, BaltimoreNCT07746388Written as Cemiplimab
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaNot yet recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07650266Written as Cemiplimab
- A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)Not yet recruitingPhase 2Regeneron PharmaceuticalsNCT07808515Written as Cemiplimab
- Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2Mayo ClinicNCT06918132Written as Cemiplimab
- A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyRecruitingPhase 3ETOP IBCSG Partners FoundationNCT06931717Written as Cemiplimab
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT07195734Written as Cemiplimab
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Regeneron PharmaceuticalsNCT06769698Written as Cemiplimab
- Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent GlioblastomasNot yet recruitingPhase 2Washington University School of MedicineNCT07620548Written as Cemiplimab
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingPhase 2Duke UniversityNCT06385262Written as Cemiplimab
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Washington University School of MedicineNCT07715734Written as Cemiplimab
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07470489Written as Cemiplimab
- Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and NeckRecruitingEarly Phase 1Vanderbilt-Ingram Cancer CenterNCT07869823Written as Cemiplimab
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2/3SWOG Cancer Research NetworkNCT06616584Written as Cemiplimab
See all 135 studies that test cemiplimab →
Given beside what is tested · 68 — cemiplimab is usual care or a partner of the new treatment
- Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient MalignanciesRecruitingPhase 2M.D. Anderson Cancer CenterNCT06444880Written as Cemiplimab
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Cemiplimab
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06900595Written as Cemiplimab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Cemiplimab
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03972657Written as Cemiplimab
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%RecruitingPhase 2Swiss Cancer InstituteNCT07020065Written as Cemiplimab
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06980038Written as Cemiplimab
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Cemiplimab (SAR439684)
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingPhase 3InSightecNCT05317858Written as Cemiplimab
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT06902376Written as Cemiplimab
- A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsRecruitingPhase 1/2Biohaven Therapeutics Ltd.NCT06384807Written as Cemiplimab
- REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell CarcinomaRecruitingPhase 1/2Regeneron PharmaceuticalsNCT07594106Written as REGN15505+Cemiplimab
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingPhase 1/2Regeneron PharmaceuticalsNCT04590326Written as Cemiplimab
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)RecruitingPhase 2NSABP Foundation IncNCT07058012Written as Cemiplimab
- A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCRecruitingPhase 1M.D. Anderson Cancer CenterNCT06826768Written as Cemiplimab
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaRecruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT07234058Written as Cemiplimab
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingPhase 1BioNTech SENCT05142189Written as Cemiplimab
- Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid TumorsRecruitingPhase 2M.D. Anderson Cancer CenterNCT06651593Written as Cemiplimab
- A Phase 1 Study of BHV-1530 in Advanced Solid TumorsRecruitingPhase 1Biohaven Therapeutics Ltd.NCT06874335Written as Cemiplimab
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingPhase 1Mohammed MilhemNCT07404332Written as Cemiplimab
Showing 20 of 68.
As the comparator · 2 — what is tested is compared with cemiplimab
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)RecruitingPhase 2NSABP Foundation IncNCT07058012Written as Cemiplimab
- A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.RecruitingPhase 2Fondazione Ricerca TraslazionaleNCT07264673Written as Cemiplimab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNov 4, 2026NCT07746388
Results posted2
Stopped1
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)TerminatedNov 3, 2026NCT06571708
Codes
What other systems call cemiplimab · ClinicalTrials.gg INT000975
- MeSH (NLM) C000627974cemiplimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6QVL057INTCEMIPLIMABConfirmed FDA, NLM
- RxNorm 2058826One source FDA
- NCI Thesaurus C121540CemiplimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627974 | cemiplimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6QVL057INT | CEMIPLIMAB | Confirmed FDA, NLM |
| RxNorm | 2058826 | — | One source FDA |
| NCI Thesaurus | C121540 | Cemiplimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.